These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29521513)

  • 1. Considerations for the cost-effective management of hepatic encephalopathy.
    Flamm SL
    Am J Manag Care; 2018 Mar; 24(4 Suppl):S51-S61. PubMed ID: 29521513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
    Neff G; Zachry W
    Pharmacoeconomics; 2018 Jul; 36(7):809-822. PubMed ID: 29651649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Health Care Burden of Hepatic Encephalopathy.
    Elsaid MI; John T; Li Y; Pentakota SR; Rustgi VK
    Clin Liver Dis; 2020 May; 24(2):263-275. PubMed ID: 32245532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomics of hepatic encephalopathy.
    Neff G
    Pharmacotherapy; 2010 May; 30(5 Pt 2):28S-32S. PubMed ID: 20412038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of hepatic encephalopathy in Latin America.
    Dávalos Moscol M; Bustios Sanchez C
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S31-5. PubMed ID: 22228878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.
    Patidar KR; Bajaj JS
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2048-61. PubMed ID: 26164219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic encephalopathy: Diagnosis and management.
    Amodio P
    Liver Int; 2018 Jun; 38(6):966-975. PubMed ID: 29624860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics for patients with hepatic encephalopathy.
    McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting compliance and persistence with treatment for hepatic encephalopathy.
    Neff G
    Pharmacotherapy; 2010 May; 30(5 Pt 2):22S-7S. PubMed ID: 20412037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic significance and economic burden of hepatic encephalopathy in liver cirrhosis in German hospitals based on G-DRG data].
    Gundling F; Rathmayer M; Koller L; Wilke M; Kircheis G; Wedemeyer H; Labenz J; Albert J; Schepp W; Lerch MM;
    Z Gastroenterol; 2020 Apr; 58(4):323-331. PubMed ID: 31863425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covert hepatic encephalopathy: not as minimal as you might think.
    Kappus MR; Bajaj JS
    Clin Gastroenterol Hepatol; 2012 Nov; 10(11):1208-19. PubMed ID: 22728384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the burden of diabetes in Poland].
    Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.